Sunshine Biopharma, Inc. (SBFM)
2.71
-0.08
(-2.87%)
USD |
NASDAQ |
Nov 06, 16:00
2.76
+0.05
(+1.85%)
After-Hours: 06:12
Sunshine Biopharma EPS Diluted (Quarterly) : -22.91 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -22.91 |
| March 31, 2026 | -50.71 |
| December 31, 2025 | -92.10 |
| September 30, 2025 | -38.80 |
| June 30, 2025 | -78.77 |
| March 31, 2025 | -87.28 |
| December 31, 2024 | -167.30 |
| September 30, 2024 | -188.99 |
| June 30, 2024 | -1988.08 |
| March 31, 2024 | -8008.00 |
| December 31, 2023 | -20932.00 |
| September 30, 2023 | -10144.00 |
| June 30, 2023 | -14236.00 |
| March 31, 2023 | -30904.00 |
| December 31, 2022 | -416412.0 |
| September 30, 2022 | -30860.00 |
| June 30, 2022 | -13600.00 |
| March 31, 2022 | -93780.00 |
| December 31, 2021 | 20.60M |
| September 30, 2021 | -635200.0 |
| June 30, 2021 | -481600.0 |
| March 31, 2021 | -1.128M |
| December 31, 2020 | -250400.0 |
| September 30, 2020 | -199200.0 |
| June 30, 2020 | -474400.0 |
| Date | Value |
|---|---|
| March 31, 2020 | -208000.0 |
| December 31, 2019 | -896000.0 |
| September 30, 2019 | -3.392M |
| June 30, 2019 | -2.096M |
| March 31, 2019 | -3.76M |
| December 31, 2018 | -6.40M |
| September 30, 2018 | -580.48M |
| June 30, 2018 | -20.48M |
| March 31, 2018 | -8.96M |
| December 31, 2017 | -7.36M |
| September 30, 2017 | -5.12M |
| June 30, 2017 | -18.24M |
| March 31, 2017 | -7.68M |
| December 31, 2016 | -46.72M |
| September 30, 2016 | -87.36M |
| June 30, 2016 | -58.56M |
| March 31, 2016 | -45.44M |
| December 31, 2015 | -104.64M |
| September 30, 2015 | -50.56M |
| June 30, 2015 | -138.24M |
| March 31, 2015 | -119.36M |
| December 31, 2014 | -145.28M |
| September 30, 2014 | -132.48M |
| June 30, 2014 | -320.00M |
| March 31, 2014 | -320.00M |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | -0.0232 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.2674 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.564M |
| Revenue (Quarterly) | 9.264M |
| Total Expenses (Quarterly) | 10.83M |
| Enterprise Value | -12.73M |
| Gross Profit Margin (Quarterly) | 25.35% |
| Profit Margin (Quarterly) | -16.88% |
| Earnings Yield | -7.55K% |
| Normalized Earnings Yield | -6771.60 |